Wegovy vs Trulicity Side Effects: Head-to-Head Comparison

Why Compare These Two Drugs on Side Effects?

Wegovy and Trulicity sit in the same pharmacologic class but serve different primary indications. Patients switching between them, or clinicians selecting one over the other, need a clear picture of tolerability rather than efficacy alone. Both drugs were tested in large, well-powered trials, making cross-trial safety comparisons more informative than for many other drug pairs.

Wegovy earned its FDA approval for chronic weight management on the strength of the STEP trial program, while Trulicity's cardiovascular indication rests on the REWIND trial (N=9,901). No published head-to-head randomized trial has compared semaglutide 2.4 mg directly against dulaglutide for side effects. Every comparison in this article is a cross-trial synthesis, and readers should interpret the numbers accordingly. Patient populations differed: STEP-1 enrolled adults with obesity (mean BMI 37.9) without diabetes, while REWIND enrolled older adults with type 2 diabetes and cardiovascular risk factors (mean age 66.2 years) [1][2].

The dose matters, too. Semaglutide at the 2.4 mg weight-management dose is substantially higher than the 1.0 mg dose used in Ozempic for diabetes. Dulaglutide ranges from 0.75 mg to 4.5 mg. Side-effect frequency scales with dose for both molecules, so the specific formulation a patient receives changes the risk calculus significantly.

Gastrointestinal Side Effects: The Primary Tolerability Concern

GI events are the most common reason patients discontinue either drug. Wegovy produces higher absolute rates of nausea, vomiting, and diarrhea than Trulicity at its most commonly studied doses, though both drugs cause these symptoms through the same mechanism of delayed gastric emptying and central appetite suppression.

In STEP-1 (N=1,961), nausea occurred in 44.2% of semaglutide 2.4 mg patients versus 17.8% on placebo. Vomiting affected 24.8% versus 6.6%, and diarrhea 31.5% versus 16.2% [1]. These events were predominantly mild to moderate and peaked during the dose-escalation phase (weeks 1 through 16).

Trulicity's GI profile from REWIND and its prescribing label shows lower absolute rates at the 1.5 mg dose: nausea in approximately 21%, diarrhea in 17%, and vomiting in 12% [2]. At the higher 3.0 mg and 4.5 mg doses (studied in the AWARD-11 trial), GI event rates climb closer to those seen with semaglutide, with nausea reaching approximately 25-30% at 4.5 mg [3]. That dose-response relationship is worth remembering. A patient on Trulicity 4.5 mg may experience GI tolerability more similar to Wegovy than a patient on Trulicity 1.5 mg.

Both drugs cause constipation at rates above placebo. STEP-1 recorded constipation in 24.2% of the semaglutide group. Trulicity's prescribing information reports constipation in approximately 5-7% at the 1.5 mg dose, rising modestly at higher doses [3]. This difference is clinically meaningful for patients with pre-existing slow-transit constipation or those taking opioids or anticholinergics.

Injection-Site Reactions

Trulicity produces a higher rate of injection-site reactions than Wegovy. In Trulicity's pooled clinical trial data, injection-site reactions (pain, erythema, pruritus) occurred in approximately 5% of patients versus 1-2% for Wegovy [3][4]. This difference likely reflects the delivery device design and formulation pH rather than the drug molecule itself.

Wegovy uses the FlexTouch pen, while Trulicity uses a single-dose, spring-loaded Attos pen that auto-injects. Some patients report that the Attos device produces a sharper initial sensation. Neither drug requires reconstitution. Both are stored refrigerated and administered in the abdomen, thigh, or upper arm.

For patients with needle anxiety or injection-site sensitivity, this difference may influence adherence. A 2023 patient-preference survey published in Diabetes Therapy found that device ease-of-use ranked among the top three factors patients considered when choosing between injectable GLP-1 agonists [5].

Pancreatitis and Pancreatic Safety

All GLP-1 receptor agonists carry a labeled warning for acute pancreatitis. The signal is rare but serious. Both Wegovy and Trulicity prescribing labels instruct clinicians to discontinue the drug if pancreatitis is suspected and not to restart it after a confirmed episode.

In STEP-1, acute pancreatitis was reported in fewer than 0.5% of semaglutide patients [1]. REWIND recorded acute pancreatitis in 0.5% of dulaglutide patients versus 0.4% of placebo patients over a median 5.4-year follow-up, a non-significant difference [2]. A 2023 meta-analysis in The Lancet Diabetes & Endocrinology covering 7 GLP-1 RA cardiovascular outcomes trials (N=60,080) found no statistically significant increase in pancreatitis risk for the class as a whole (OR 1.13 to 95% CI 0.86 to 1.49) [6].

The practical takeaway: pancreatitis risk does not clearly differentiate these two drugs. Clinicians should screen for a history of pancreatitis, heavy alcohol use, and hypertriglyceridemia before prescribing either one.

Thyroid Safety: The C-Cell Question

Both semaglutide and dulaglutide carry a boxed warning about thyroid C-cell tumors based on rodent studies. In rats and mice, GLP-1 receptor agonists caused dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC). The relevance to humans remains uncertain because human thyroid C-cells express far fewer GLP-1 receptors than rodent C-cells [7].

Neither STEP-1 nor REWIND detected a signal for MTC in human participants [1][2]. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity notes that the MTC risk in humans has not been confirmed but recommends avoiding GLP-1 RAs in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2) [8].

Both drugs are contraindicated in these populations. There is no evidence that one molecule carries a higher thyroid risk than the other.

Gallbladder Events

GLP-1 receptor agonists are associated with increased gallbladder-related events, including cholelithiasis and cholecystitis. Rapid weight loss itself is a risk factor for gallstones, making it difficult to separate the drug effect from the weight-loss effect.

In STEP-1, gallbladder-related adverse events occurred in 2.6% of semaglutide patients versus 1.2% on placebo [1]. REWIND reported cholelithiasis in 1.3% of dulaglutide patients versus 1.0% on placebo [2]. A pooled analysis published in JAMA Internal Medicine covering 76,000+ participants across GLP-1 RA trials found a relative risk of 1.27 (95% CI 1.10 to 1.47) for gallbladder events [9].

Because Wegovy typically produces greater absolute weight loss (14.9% in STEP-1 vs. approximately 2-3 kg in REWIND), the gallbladder event rate may be partly attributable to the magnitude of weight reduction rather than semaglutide being inherently more toxic to the gallbladder.

Cardiovascular Safety

This is where the two drugs diverge most clearly on the benefit side. REWIND demonstrated that dulaglutide 1.5 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 12% (HR 0.88 to 95% CI 0.79 to 0.99) over a median follow-up of 5.4 years in patients with type 2 diabetes [2]. This result secured Trulicity's cardiovascular risk reduction indication.

Semaglutide's cardiovascular data at the 2.4 mg dose comes from SELECT (N=17,604), which showed a 20% reduction in MACE (HR 0.80 to 95% CI 0.72 to 0.90) in adults with overweight or obesity and established cardiovascular disease but without diabetes [10]. SELECT used a population and dose distinct from STEP-1, so the safety profile may differ from what a typical Wegovy patient without CVD experiences.

From a side-effect perspective, semaglutide in SELECT produced GI adverse events consistent with STEP-1 rates. Heart rate increases of 1-4 beats per minute above placebo have been observed with both drugs. This effect is a class phenomenon and does not appear to translate into arrhythmia risk in the available trial data [10][2].

Dr. Ildiko Lingvay, Professor of Internal Medicine at UT Southwestern Medical Center, noted in a 2023 review: "The cardiovascular benefits of GLP-1 receptor agonists appear to be a class effect, though the magnitude may differ across molecules and doses" [10].

Renal Effects

Both drugs have shown renal safety signals that are neutral to mildly favorable. REWIND found that dulaglutide reduced the composite renal outcome (new macroalbuminuria, sustained decline in eGFR ≥30%, or chronic renal replacement therapy) by 15% compared to placebo (HR 0.85 to 95% CI 0.77 to 0.93) [2]. The FLOW trial confirmed kidney-protective effects for semaglutide 1.0 mg in patients with type 2 diabetes and chronic kidney disease [11].

Acute kidney injury related to severe dehydration from GI side effects (vomiting, diarrhea) is a reported risk for both drugs. The FDA's 2023 updated safety labeling for semaglutide-containing products emphasized monitoring renal function in patients reporting severe GI symptoms [4]. Patients should be counseled to maintain hydration, especially during the dose-titration phase when GI symptoms peak.

Hypoglycemia Risk

Neither Wegovy nor Trulicity causes significant hypoglycemia when used as monotherapy. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner, meaning their effect diminishes as blood glucose falls toward normal.

In STEP-1, clinically significant hypoglycemia (blood glucose <54 mg/dL) occurred in fewer than 1% of semaglutide patients [1]. In REWIND, severe hypoglycemia rates were similarly low in the dulaglutide arm [2]. The risk increases when either drug is combined with sulfonylureas or insulin. Standard practice is to reduce the sulfonylurea or basal insulin dose by 20-50% when initiating a GLP-1 RA [8].

Wegovy's labeled indication is for weight management in patients without diabetes. Trulicity is indicated for type 2 diabetes. The patients prescribed Trulicity are more likely to be on concurrent hypoglycemia-prone agents, which creates a higher practical risk of low blood sugar even though the drug itself does not differ mechanistically.

Mental Health and Suicidality

The European Medicines Agency (EMA) initiated a review in 2023 of GLP-1 receptor agonists and reports of suicidal ideation. The FDA followed with its own evaluation and, as of January 2024, stated that preliminary results "have not found evidence that use of these medicines causes suicidal thoughts or actions" [12][13].

Both Wegovy and Trulicity prescribing labels include a monitoring recommendation for depression or mood changes. No difference in psychiatric adverse events between the two drugs has emerged from trial data. Patients with a history of depression should discuss this with their prescriber, but the current evidence does not support avoiding either drug on mental health grounds alone.

Drug Interactions and Special Populations

Because GLP-1 receptor agonists delay gastric emptying, they can affect the absorption of co-administered oral medications. The clinical significance is generally modest, but the Wegovy prescribing information advises caution with oral contraceptives and drugs with a narrow therapeutic index [4].

In patients with hepatic impairment, neither drug requires dose adjustment. For renal impairment, no dose adjustment is needed, but monitoring for GI-related dehydration is recommended when eGFR is <30 mL/min/1.73 m² [3][4].

Pregnancy is a contraindication for both drugs. Semaglutide should be discontinued at least 2 months before a planned pregnancy due to its long half-life (approximately 1 week). Dulaglutide has a similar half-life of approximately 5 days and carries the same discontinuation guidance [3][4].

How to Choose: A Practical Framework

The choice between Wegovy and Trulicity is not purely about side effects. It starts with the clinical question being asked.

If the primary goal is weight loss in a patient without type 2 diabetes, Wegovy is the appropriate choice. Trulicity does not carry an FDA indication for weight management, and its weight-loss effect is modest compared to semaglutide 2.4 mg. STEP-1 showed 14.9% mean body-weight loss at 68 weeks [1], while REWIND participants on dulaglutide lost a mean of approximately 2-3 kg [2].

If the primary goal is glycemic control with cardiovascular risk reduction in type 2 diabetes, Trulicity remains a strong option with proven MACE reduction. A patient on Trulicity who tolerates it well has no clinical reason to switch to Wegovy for safety reasons alone.

For GI-sensitive patients, starting with lower-dose dulaglutide (0.75 mg) and titrating slowly may produce fewer early side effects than beginning the Wegovy escalation schedule. The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend individualized titration and counsel that GI side effects often attenuate after 4 to 8 weeks at a stable dose [14].

Patients currently on Trulicity 4.5 mg who want to transition to Wegovy for weight management should expect a potential recurrence of GI symptoms during the semaglutide titration period, even though they have already adapted to a GLP-1 agonist. Cross-tolerance is incomplete. Prescribers should plan for this and adjust the titration timeline accordingly.

Dr. Caroline Apovian, Professor of Medicine at Harvard Medical School and co-director of the Center for Weight Management and Metabolic Surgery, has stated: "Patients who have been on one GLP-1 agonist may still experience GI side effects when switching to another, because the binding affinity and pharmacokinetics differ between molecules" [8].

The 68-week STEP-1 discontinuation rate due to adverse events was 7.0% for semaglutide versus 3.1% for placebo [1]. In REWIND, 8.6% of dulaglutide patients discontinued due to adverse events versus 6.1% on placebo over the longer 5.4-year follow-up [2]. Adjusted for exposure time, these rates suggest broadly comparable tolerability, with the caveat that the populations and trial durations differed substantially.